var data={"title":"Betamethasone and gentamicin (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Betamethasone and gentamicin (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/44065?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=betamethasone-and-gentamicin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Betamethasone and gentamicin (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20303201\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sandoz Pentasone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311418\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Ophthalmic;</li>\n      <li>\n        Antibiotic, Otic;</li>\n      <li>\n        Antibiotic/Corticosteroid, Ophthalmic;</li>\n      <li>\n        Antibiotic/Corticosteroid, Otic;</li>\n      <li>\n        Corticosteroid, Ophthalmic;</li>\n      <li>\n        Corticosteroid, Otic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311452\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Improvement is typically seen within 48 hours and clearing of symptoms within 14 days. Gradual withdrawal from therapy is necessary following long-term use for chronic conditions. Reduce dosage gradually for satisfactory response and discontinue upon cure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic infection/inflammation:</b> Topical: Instill 2 drops into conjunctival sac of affected eye(s) 3 to 4 times daily; during acute stage, may administer 2 drops every 2 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otic infection/inflammation:</b> Topical: Instill 3 to 4 drops into affected ear(s) 3 times daily or as directed. Alternatively, the manufacturer suggests that a cotton wick may be placed in the canal then saturated with solution every 4 hours; cotton wick should be replaced every 24 hours. Reassess for ototoxicity in 5 to 7 days and regularly thereafter during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311451\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Ophthalmic or otic infection/inflammation:</b> Children &ge;8 years and Adolescents: Topical: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311453\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311454\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Dosage adjustment however is unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311455\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Dosage adjustment however is unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311464\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, ophthalmic/otic: Gentamycin 0.3% and betamethasone 0.1% (7.5 mL) [contains benzalkonium chloride]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311463\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311456\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For topical use only. The same bottle should not be used to treat ocular and otic infections, nor should it be used by more than one person.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic use: Contact lenses should not be worn during therapy with ophthalmic solution. Apply solution by tilting head back and instilling in conjunctival sac and close eye(s). Do not touch dropper to eye or any other surface. Apply light finger pressure on lacrimal sac for 1 minute following instillation. Apply ointment into pocket between eyeball and lower lid; patient should look downward before closing eye.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic use: Carefully clear the ear canal of cerumen and debris. Patient should lie down with affected ear upward and medication instilled. Patients should remain in the position for several minutes to allow penetration of solution. Alternatively, the manufacturer suggests that a cotton wick may be placed in the canal then saturated with solution every 4 hours; cotton wick should be replaced every 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311420\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ophthalmic infection/inflammation:</b> Treatment of non-purulent, susceptible infections of the anterior segment of the eye; inflammatory conditions also requiring antimicrobial therapy; adjunct to systemic therapy in resistant infections</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Otic infection/inflammation:</b> Treatment of external ear lesions (eg, otitis externa, contact dermatitis secondarily infected with susceptible bacteria)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311439\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Also see individual agents.</p>\n    <p style=\"text-indent:0em;\">Hypersensitivity: Hypersensitivity (ophthalmic; includes ocular hyperemia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Burning sensation of eyes, increased intraocular pressure, ocular edema, stinging of eyes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Ototoxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311424\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to betamethasone or other corticosteroids, gentamicin or other aminoglycosides, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications based on route of administration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic use: Epithelial herpes simplex keratitis, vaccinia, varicella, and many other viral disease of the cornea and conjunctiva; mycobacterial infections of the eye or ear, trachoma, fungal diseases of ocular structures; following removal of a corneal foreign body or in the presence of acute local viral lesions; absent or perforated tympanic membranes; concurrent use of soft contact lenses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic use: Non-intact tympanic membrane (broken, absent or perforated tympanic membranes or with presence of surgical ear tubes)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311425\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Discontinue use for signs/symptoms of hypersensitivity (eg, irritation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Steroids may mask infection, enhance existing ocular infection, or reactivate latent disease (eg, herpes infection of cornea); prolonged use may result in secondary bacterial or fungal superinfection due to immunosuppression. Black patients may be more susceptible to developing anterior uveitis. Lack of prompt clinical response may indicate resistance to therapy and warrant discontinuation of therapy and further evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Avoid prolonged use of corticosteroids, which may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Risk may increase in patients with family history of open-angle glaucoma, with myopia, or with diabetes. Monitor intraocular pressure (routinely if duration of therapy is &gt;10 days). Topical corticosteroid use in patients with thinning of cornea or sclera has also been associated with perforation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Otic effects: Animal studies indicate that topical gentamicin may be absorbed from the external ear canal; potential toxicity to the vestibulocochlear nerve should be considered. Ototoxicity has been reported with gentamicin (Helel, 1997; Stockwell, 2001). Use for shortest duration possible and discontinue for hearing loss, tinnitus, vertigo or imbalance. Assess for ototoxicity periodically.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Corneal ulcers: Corneal ulcers due to pseudomonas aeruginosa should not be treated initially with combination antibacterial/corticosteroid. If adequate response to initial therapy with antibiotic then may add corticosteroid to minimize corneal fibrous reaction and scarring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cataract surgery patients: Use following cataract surgery may delay healing or increase the incidence of bleb formation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzalkonium chloride: Solution contains benzalkonium chloride which may be adsorbed by contact lenses; contact lenses should not be worn during treatment of ophthalmic infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For topical use only. Do not inject subconjunctivally or introduce directly into anterior chamber of the eye. Use of topical corticosteroids to prevent scarring in the healing stages of herpes simplex infection should be done with extreme caution and close observation; may reactivate disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344305\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344303\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=89335&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311421\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311423\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if betamethasone/gentamicin is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311462\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Intraocular pressure (regularly if treatment &gt;10 days); slit-lamp exam for dendritic keratitis; secondary infection (with prolonged use); signs/symptoms of ototoxicity (5-7 days after initiation then regularly thereafter)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311444\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20311446\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Absorption: Gentamicin: Ophthalmic drops: Systemic absorption: Undetected (&lt;0.5 mcg/mL) (Trope 1979)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059529\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Argensol (ID);</li>\n      <li>Bedicort G (LV);</li>\n      <li>Belogent (HR);</li>\n      <li>Belohent (UA);</li>\n      <li>Benoson G (ID);</li>\n      <li>Beprogent (PK, SG, TH);</li>\n      <li>Betacorten G (IL);</li>\n      <li>Betagel-G (IN);</li>\n      <li>Betagen (CO, MY, TH);</li>\n      <li>Betagenic (LK);</li>\n      <li>Betagent (PK);</li>\n      <li>BetazonGent (BG);</li>\n      <li>Betogenta (BR);</li>\n      <li>Dipgen (LK);</li>\n      <li>Diprogenta (AE, AT, BG, BH, BR, CH, CO, DE, ES, HR, ID, IL, KW, LK, MY, PH, PK, PL, PT, PY, QA, SA, SG, VE, VN, ZA);</li>\n      <li>Diprogenta SP (PE);</li>\n      <li>Diprosone G (MX);</li>\n      <li>Diprosta (ID);</li>\n      <li>Eftigentacort (VN);</li>\n      <li>Epione (PT);</li>\n      <li>Garasone (AE, BH, BR, HK, HU, ID, KW, PH, SA);</li>\n      <li>Genjistone (KR);</li>\n      <li>Genobet (BD);</li>\n      <li>Genta Cort-B (IN);</li>\n      <li>Gental Beta (PY);</li>\n      <li>Gentate-B (IN);</li>\n      <li>Lupiderm-G (IN);</li>\n      <li>Mixgen (CL);</li>\n      <li>Nivera (KR);</li>\n      <li>Novason (KR);</li>\n      <li>Oftagen Compuesto (CL);</li>\n      <li>Oftalmogenta (CO, EC);</li>\n      <li>Sonigen (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    H&egrave;lel A, &ldquo;Aminoglycoside Eardrops and Ototoxicity,&rdquo; <i>Can Adverse Drug React Newsl</i>,1997, 7(2):7-10.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandoz Pentasone (betamethasone/gentamicin) [product monograph]. Boucherville, Canada; July 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stockwell M, &ldquo;Gentamicin Ear Drops and Ototoxicity: Update,&rdquo; <i>Can Adverse Drug React Newsl</i>, 2001, 11(1):5-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trope GE, Lawrence JR, Hind VM, et al, &ldquo;Systemic Absorption of Topical and Subconjunctival Gentamicin,&rdquo; <i>Br J Ophthalmol</i>, 1979, 63(10):692-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/betamethasone-and-gentamicin-united-states-not-available-drug-information/abstract-text/508681/pubmed\" target=\"_blank\" id=\"508681\">508681</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 89335 Version 62.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F20303201\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F20311418\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F20311452\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F20311451\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F20311453\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20311454\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20311455\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F20311464\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F20311463\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20311456\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F20311420\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F20311439\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F20311424\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F20311425\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F20344305\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F20344303\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F20311421\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20311423\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20311462\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F20311444\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20311446\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059529\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/89335|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=betamethasone-and-gentamicin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Betamethasone and gentamicin (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}